Key result
CaMKII inhibitors (AIP or KN93) suppressed cardiac fibroblast proliferation and decreased extracellular matrix secretion induced by angiotensin II or electrical field stimulation in vitro.
CaMKII mediates cardiac fibroblast proliferation and extracellular matrix secretion, highlighting its potential as a therapeutic target for myocardial fibrosis.
Answers are grounded in this paper and cite their sources.
CaMKII inhibition attenuates profibrotic fibroblast responses in vitro; leaves open therapeutic translation to myocardial fibrosis.
Calcium-calmodulin-dependent protein kinase II (CaMKII) is one of the main protein kinases mediating intracellular Ca changes. It is also involved in the process of cardiac diseases, such as cardiac hypertrophy, but its effects on myocardial fibrosis remain unclear. The present study investigates whether CaMKII is involved in cardiac fibroblast proliferation and extracellular matrix (ECM) secretion induced by angiotensin II (AngII) or electrical field stimulation (EFS) in cultured neonatal rat cardiac fibroblasts. Cardiac fibroblast proliferation was assessed by a cell survival assay (MTT) and manual cell enumeration. Cellular matrix production was demonstrated by matrix metalloproteinases (MMP) 1, 2, 9, and collagen I/III messenger RNA expression, MMP-2, 9 protein expression, and secretion of transforming growth factor beta1 and tumor necrosis factor alpha. Either AngII or EFS promoted cardiac fibroblast proliferation and ECM secretion, while also up-regulating expression of CaMKII deltaB and deltaC. More importantly, CaMKII inhibitors, autocamtide-2-related inhibitory peptide (AIP 5 microM) or KN93 (0.5 microM), suppressed cardiac fibroblast proliferation, inhibited the excretion of transforming growth factor beta1 and tumor necrosis factor alpha, decreased the messenger RNA expression of MMP-1, 2, 9 and collagen I/III, and decreased the protein expression of MMP-2, 9. These results suggest that CaMKII mediates cardiac fibroblast proliferation and ECM secretion induced by either AngII or EFS.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2010) studied Myocardial fibrosis. CaMKII inhibitors (autocamtide-2-related inhibitory peptide [AIP] or KN93) was evaluated on Cardiac fibroblast proliferation and extracellular matrix (ECM) secretion. CaMKII inhibitors (AIP or KN93) suppressed cardiac fibroblast proliferation and decreased extracellular matrix secretion induced by angiotensin II or electrical field stimulation in vitro.
Synapse has enriched 10 related papers. Consider them for comparative context: